Phase I, Open-Label, 3-Way Crossover Trial in Healthy Volunteers to Determine the Drug-Drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Trial Profile

Phase I, Open-Label, 3-Way Crossover Trial in Healthy Volunteers to Determine the Drug-Drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Rifampicin (Primary) ; Simeprevir (Primary)
  • Indications Hepatitis C; Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 29 Jan 2009 Planned patient numbers amended from 18 to 21 as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top